



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 09 May 2022 (#18)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office)

For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.

- FMHS contact: cdevries@sun.ac.za
- Stellenbosch Campus contact lizelk@sun.ac.za.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html

- **NOT-HD-22-018 Notice of Intent to Publish a Funding Opportunity Announcement for Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network Clinical Research Centers.** The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to participate in a research program cooperative agreement to support the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC³H-IN). The Network will expand successes achieved by PATC³H to new geographic settings with limited implementation science (IS) research capacity and/or at-risk populations who are poorly represented in international adolescent HIV research (e.g., sexual and gender minorities; commercial sex workers; drug users) and stimulate much needed IS research in a neglected area of public health significance: prevention of new HIV infections among adolescents at risk and the identification of, and linkage and retention to care of and long-term viral suppression among youth living with HIV in low-to-middle income countries (LMICs). These settings must have an HIV epidemic density defined by [UNAIDS estimates](#) as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV incidence among youth ages 10 to 24 years of 0.01% or more. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. To apply, investigators will be expected to demonstrate successful collaborations with local agencies and regulatory bodies, including policy makers and program leaders and implementers, to advance achievement of the research objectives and maximize sustainability of efficacious interventions and best practices. First Estimated Application Due Date: November 30, 2022.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices of Special Interest

[NOT-CA-22-063](#) **Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy.** The overall goal of this Notice of Special Interest (NOSI) is to promote mechanistic research aimed at better understanding the pathophysiology of immune-related adverse events (irAEs). It is anticipated that the mechanistic research supported through this NOSI will build the foundational knowledge which will ultimately lead to better strategies to predict, prevent and/or ameliorate toxicities that can arise as a consequence of current immunotherapeutic regimens, and improve treatment outcomes. The proposed research can be basic or translational but should be focused on revealing the mechanisms underlying irAEs. Single investigators and/or multidisciplinary teams with relevant expertise in the research area proposed and/or patient characterization and selection are encouraged to apply. First Available Due Date: June 5, 2022.

[NOT-CA-22-085](#) **Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer.** The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms. Studies that integrate expertise from multiple disciplines, incorporate state-of-the-art, human-relevant models (e.g., organoid or patient-derived xenograft models) and utilize advanced technologies and methods are strongly encouraged. Applications that will be considered nonresponsive to this NOSI will include those focused on: Clinical trials; Symptoms not related to cancer or cancer treatment; Projects that lack cancer models, specimens or cells. This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through May 8, 2027.

[NOT-OD-22-125](#) **Notice of Special Interest (NOSI): IMPROVE Initiative: Implementation Science to Advance Maternal Health and Maternal Health Equity.** The Office of the Director of the National Institutes of Health (NIH) announces this new funding opportunity to advance the goals of the NIH Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone ([IMPROVE](#)) Initiative. IMPROVE aims to understand the biological, behavioral, environmental, sociocultural, and structural factors that affect pregnancy-related and pregnancy-associated morbidity and mortality and build an evidence base for improved care and outcomes. The initiative promotes research to address health disparities associated with pregnancy-related and pregnancy-associated morbidity and mortality. The purpose of this Notice of Special Interest (NOSI) is to stimulate dissemination and implementation research on innovative approaches built on evidence-based findings from foundational research on factors that contribute to maternal morbidity and mortality (MMM). This NOSI will support the development and implementation of strategies to inform integrated efforts involving policy and practice changes to improve preconception, pregnancy, perinatal, and postpartum care and advance maternal health and maternal health equity. NIH plans to implement in fiscal year 2023 several activities to enhance research to advance maternal health. In order to maximize the impact and leverage any resources generated from projects funded in response to this NOSI, preference will be given to projects that can be achieved within a three-year timeframe (R21 and R03 applications are limited to project periods of two years or less). Specific to R01 applications, the maximum project period that will be accepted is three years. First Available Due Date: June 05, 2022. Expiration Date: July 17, 2022

Funding Opportunity Announcements (FOA)

1. Policy and Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) Healthcare Disparities: Access, Utilization, and Quality (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-23-024](#)

Type: R01

Application Due Date: October 20, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits Research Project Grant (R01) applications for projects designed to exploit variations (e.g., geographic, temporal) in social and health care policies to employ experimental, quasi-experimental, or other innovative approaches to uncover mechanisms driving disparities in care (i.e., access, utilization, and quality) for persons living with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).

Budget: NIA intends to commit \$4,500,000 in fiscal year 2023 to fund 5-6 awards. Application budgets are limited to \$500,000 per year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105